Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial.
Merkel PA, Silliman NP, Denton CP, Furst DE, Khanna D, Emery P, Hsu VM, Streisand JB, Polisson RP, Akesson A, Coppock J, van den Hoogen F, Herrick A, Mayes MD, Veale D, Seibold JR, Black CM, Korn JH; CAT-192 Research Group; Scleroderma Clinical Trials Consortium. Merkel PA, et al. Among authors: korn jh. Arthritis Rheum. 2008 May 15;59(5):699-705. doi: 10.1002/art.23564. Arthritis Rheum. 2008. PMID: 18438905 Free PMC article. Clinical Trial.
Durometry for the assessment of skin disease in systemic sclerosis.
Kissin EY, Schiller AM, Gelbard RB, Anderson JJ, Falanga V, Simms RW, Korn JH, Merkel PA. Kissin EY, et al. Among authors: korn jh. Arthritis Rheum. 2006 Aug 15;55(4):603-9. doi: 10.1002/art.22093. Arthritis Rheum. 2006. PMID: 16874783 Free article.
Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192.
Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, Silliman N, Streisand J, Powell J, Akesson A, Coppock J, Hoogen Fv, Herrick A, Mayes MD, Veale D, Haas J, Ledbetter S, Korn JH, Black CM, Seibold JR; Cat-192 Study Group; Scleroderma Clinical Trials Consortium. Denton CP, et al. Among authors: korn jh. Arthritis Rheum. 2007 Jan;56(1):323-33. doi: 10.1002/art.22289. Arthritis Rheum. 2007. PMID: 17195236 Free article. Clinical Trial.
Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.
Khanna D, Clements PJ, Furst DE, Korn JH, Ellman M, Rothfield N, Wigley FM, Moreland LW, Silver R, Kim YH, Steen VD, Firestein GS, Kavanaugh AF, Weisman M, Mayes MD, Collier D, Csuka ME, Simms R, Merkel PA, Medsger TA Jr, Sanders ME, Maranian P, Seibold JR; Relaxin Investigators and the Scleroderma Clinical Trials Consortium. Khanna D, et al. Among authors: korn jh. Arthritis Rheum. 2009 Apr;60(4):1102-11. doi: 10.1002/art.24380. Arthritis Rheum. 2009. PMID: 19333948 Free PMC article. Clinical Trial.
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, Korn JH, Simms RW, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman MH, Collier DH, Weinstein A, Furst DE, Jiménez SA, White B, Seibold JR, Wigley FM; Scleroderma Clinical Trials Consortium. Merkel PA, et al. Among authors: korn jh. Arthritis Rheum. 2002 Sep;46(9):2410-20. doi: 10.1002/art.10486. Arthritis Rheum. 2002. PMID: 12355489 Free article.
Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.
Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, Rich E, Carpentier P, Molitor J, Seibold JR, Hsu V, Guillevin L, Chatterjee S, Peter HH, Coppock J, Herrick A, Merkel PA, Simms R, Denton CP, Furst D, Nguyen N, Gaitonde M, Black C. Korn JH, et al. Arthritis Rheum. 2004 Dec;50(12):3985-93. doi: 10.1002/art.20676. Arthritis Rheum. 2004. PMID: 15593188 Free article. Clinical Trial.
A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease.
Postlethwaite AE, Wong WK, Clements P, Chatterjee S, Fessler BJ, Kang AH, Korn J, Mayes M, Merkel PA, Molitor JA, Moreland L, Rothfield N, Simms RW, Smith EA, Spiera R, Steen V, Warrington K, White B, Wigley F, Furst DE. Postlethwaite AE, et al. Arthritis Rheum. 2008 Jun;58(6):1810-22. doi: 10.1002/art.23501. Arthritis Rheum. 2008. PMID: 18512816 Free PMC article. Clinical Trial.
Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.
Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, Korn JH, Merkel PA, Rothfield N, Wigley FM, Moreland LW, Silver R, Steen VD, Weisman M, Mayes MD, Collier DH, Medsger TA Jr, Seibold JR; Relaxin Study Group; Scleroderma Clinical Trials Consortium. Khanna D, et al. Among authors: korn jh. J Rheumatol. 2005 May;32(5):832-40. J Rheumatol. 2005. PMID: 15868618 Clinical Trial.
Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
Wigley FM, Korn JH, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman M, Martin R, Collier DH, Weinstein A, Furst DE, Jimenez SA, Mayes MD, Merkel PA, Gruber B, Kaufman L, Varga J, Bell P, Kern J, Marrott P, White B, Simms RW, Phillips AC, Seibold JR. Wigley FM, et al. Among authors: korn jh. Arthritis Rheum. 1998 Apr;41(4):670-7. doi: 10.1002/1529-0131(199804)41:4<670::AID-ART14>3.0.CO;2-I. Arthritis Rheum. 1998. PMID: 9550476 Clinical Trial.
133 results